Infinity Announces First Quarter 2009 Results Conference Call
28. April 2009 10:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 28, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Infinity management...
Infinity Presents New Preclinical Data From Its Heat Shock Protein 90 Inhibitor Program At AACR
21. April 2009 15:00 ET
|
Infinity Pharmaceuticals, Inc.
DENVER, Colo. and CAMBRIDGE, Mass., April 21, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today presented data from its heat shock protein 90 (Hsp90) inhibitor program that...
Infinity Presents Preclinical Data Demonstrating Potential of Hedgehog Pathway Inhibition With IPI-926 in Multiple Cancer Settings
21. April 2009 10:00 ET
|
Infinity Pharmaceuticals, Inc.
DENVER and CAMBRIDGE, Mass., April 21, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today presented preclinical data from studies of IPI-926, its oral Hedgehog pathway...
Infinity Halts RING Trial in Advanced Gastrointestinal Stromal Tumors
15. April 2009 09:15 ET
|
Infinity Pharmaceuticals, Inc.
-- Decision Based On Recommendation Received Tuesday Night From
Independent Data Monitoring Committee --
-- Infinity Reaffirms Commitment to Hsp90 Development and Cash
...
Infinity to Present Preclinical Data From Its Hsp90 Inhibitor Program and Its Hedgehog Signaling Pathway Inhibitor Program At AACR Meeting
08. April 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 8, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting...
Infinity Announces Leadership Promotions
07. April 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 7, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced two leadership...
Infinity Initiates International Phase 2 Trial of IPI-504 in Combination With Herceptin(r) in Patients With HER2-Positive Breast Cancer
30. März 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the initiation of a...
Infinity Presents the Chemistry and Discovery of IPI-926, Its Novel Hedgehog Signaling Pathway Inhibitor, At ACS Meeting
25. März 2009 11:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and SALT LAKE CITY, March 25, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced data...
Infinity to Present At the Future Leaders Conference
23. März 2009 07:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 23, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven H. Holtzman,...
Infinity to Present the Discovery of IPI-926, Its Hedgehog Signaling Pathway Inhibitor, At ACS Meeting
17. März 2009 07:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be...